Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 596

[116] Brewster ME, Hora MS, Simpkins JW, Bodor N. Use of 2-hydroxypropyl-ß-cyclodex-
trin as a solubilizing and stabilizing excipient for protein drugs. Pharm Res 1991;8:
792-5.
[117] Charman SA, Mason KL, Charman WN. Techniques for assessing the effects of phar-
maceutical excipients on the aggregation of porcine growth hormone. Pharm Res
1993;10:954-62.
[118] Ressing ME, Jiskoot W, Talsma H, van Ingen CW, Beuvery EC, Crommelin DJA. The
influence of sucrose, dextran, and hydroxypropyl-ß-cyclodextrin as lyoprotectants for a
freeze-dried mouse IgG monoclonal antibody (MN12). Pharm Res 1992;9:266-70.
[119] Prankerd RJ, Stone HW, Sloan KB, Perrin JH. Degradation of aspartame in acidic aque-
ous media and its stabilization by complexation with cyclodextrins or modified cyclo-
dextrins. Int J Pharm 1992;88:189-99.
[120] Hora MS, Rana RK, Smith FW. Lyophilized of recombinant tumor necrosis factor.
Pharm Res 1992;9:33-6.
[121] Katakam M, Banga AK. Aggregation of proteins and its prevention by carbohydrate
excipients: albumins and -globulin. J Pharm Pharmacol 1995;47:103-7.
[122] Izutsu K, Yoshioka S, Kojima S. Increased stabilizing effects of amphiphilic excipients
on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices.
Pharm Res 1995;12:838-43.
[123] De Rosa G, Iommelli R, La Rotonda MI, Miro A, Quaglia F. Influence of the co-encap-
sulation of different non-ionic surfactants on the properties of PLGA insulin-loaded
microspheres. J Control Release 2000;69:283-95.
[124] Sturesson C, Carlfors J. Incorporation of protein in PLG-microspheres with retention of
bioactivity. J Control Release 2000;67:171-8.
[125] Sanchez A, Tobio M, Gonzalez L, Fabra A, Alonso MJ. Biodegradable micro- and nanopar-
ticles as long-term delivery vehicles for interferon-. Eur J Pharm Sci 2003;18:221-9.
[126] Chen L, Apte RN, Cohen S. Characterization of PLGA microspheres for the controlled
delivery of IL-1a for tumor immunotherapy. J Control Release 1997;43:261-72.
[127] Kwon YM, Baudys M, Knutson K, Kim SW. In situ study of insulin aggregation
induced by water-organic solvent interface. Pharm Res 2001;18:1754-59.
[128] Castellanos IJ, Crespo R, Griebenow K. Poly(ethylene glycol) as stabilizer and emulsi-
fying agent: a novel stabilization approach preventing aggregation and inactivation of
proteins upon encapsulation in bioerodible polyester microspheres. J Control Release
2003;88:135-45.
[129] Kumar V, Kalonia DS. Removal of peroxides in polyethylene glycols by vacuum dry-
ing: implications in the stability of biotech and pharmaceutical formulations. AAPS
Pharm Sci Tech 2006;7:62.
[130] Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in
recombinant monoclonal antibody HER2. J Pharm Sci 1997;86:1250-55.
[131] Fransson JR. Oxidation of human insulin-like growth factor I in formulation studies.
3. Factorial experiments of the effects of ferric ions, EDTA, and visible light on methi-
onine oxidation and covalent aggregation in aqueous solution. J Pharm Sci 1997;86:
1046-50.
[132] Langer R. Polymer-controlled drug delivery systems. Acc Chem Res 1993;26:537-42.
[133] Rajendra V, Chen Y, Brook MA. Structured hydrophilic domains on silicone elastomers.
Polym Chem 2010;1:312-20.
[134] Prashant B, Sutar PB, Mishra RK, Pal K, Banthia AK. Development of pH sensitive
polyacrylamide grafted pectin hydrogel for controlled drug delivery system. J Mater Sci
Mater Med 2008;19:2247-53.